-
Those patients undergoing decompression alone may postoperatively develop progression or the new appearance of olisthy, while those primarily fused rarely show further increase or a new onset of slip.
-
-
Sources of funding for pharmaceutical research has come under scrutiny in the last decade as academic and government sources of funding have become increasingly scarce and the pharmaceutical industry has become the main source of research dollars. But the issue of objectivity has been raised, and some have even suggested that negative studies, that is studies that show a drug in an unfavorable light, may never be published. The American Medical Association has recently tackled this issue.
-
Evidence suggests that Erythropoietin acts by stimulating neuroprotective pathways, including the protein kinase B cascade and the transcription factor nuclear factor-kB pathway, to activate antiapoptotic and antioxidant factors.
-
Leflunomides immunomodulatory activity derives from its action as a competitive inhibitor of the rate-limiting enzyme necessary for pyrimidine synthesis.
-
This is the latest of several important publications by Dr. Fullerton and her colleagues, at The University of California at San Francisco, describing details of the epidemiology of pediatric stroke during the last 2 decades of the 20th century.
-
These papers and the accompanying editorial by Rascol bring attention to a known but under-recognized complication of ergot derivatives.
-
Treatment of TGA patients with antiplatelet treatment is likely warranted, particularly if there are underlying vascular risk factors.
-
Converging evidence implicates both protein aggregation as well as oxidative damage in mitochondrial dysfunction in Parkinsons disease pathogenesis. It is likely that these factors may interact.
-
These findings are amongst the most direct data to date that oxidative damage plays a critical role in normal human aging.